Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the global burden of disease study. Lancet. 2020;395(10219):200–11.

Article  PubMed  PubMed Central  Google Scholar 

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32(3):858–73.

Article  PubMed  Google Scholar 

Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, McIntyre L, Ostermann M, Prescott HC, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063–143.

Article  PubMed  Google Scholar 

Shi R, Hamzaoui O, De Vita N, Monnet X, Teboul JL. Vasopressors in septic shock: which, when, and how much? Ann Transl Med. 2020;8(12):794.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weitzman S, Berger S. Clinical trial design in studies of corticosteroids for bacterial infections. Ann Intern Med. 1974;81(1):36–42.

Article  CAS  PubMed  Google Scholar 

Hahn EO, Houser HB, Rammelkamp CH Jr, Denny FW, Wannamaker LW. Effect of cortisone on acute streptococcal infections and poststreptococcal complications. J Clin Invest. 1951;30(3):274–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317(11):653–8.

Article  CAS  PubMed  Google Scholar 

Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862–71.

Article  CAS  PubMed  Google Scholar 

Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378(9):809–18.

Article  CAS  PubMed  Google Scholar 

Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, Billot L, Correa M, Glass P, Harward M, et al. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378(9):797–808.

Article  CAS  PubMed  Google Scholar 

Song B, Zheng X, Fu K, Liu C. Early use of low-dose hydrocortisone can reduce in-hospital mortality in patients with septic shock: a systematic review and meta-analysis. Medicine (Baltimore). 2024;103(48):e40635.

Article  PubMed  Google Scholar 

Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, Bogatsch H, Briegel J, Engel C, Gerlach H, et al. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA. 2016;316(17):1775–85.

Article  CAS  PubMed  Google Scholar 

Reinhart K, Brunkhorst F, Bone H, Gerlach H, Gründling M, Kreymann G, Kujath P, Marggraf G, Mayer K, Meier-Hellmann A, et al. Diagnosis and therapy of sepsis. Guidelines of the German sepsis society Inc. and the German interdisciplinary society for intensive and emergency medicine. Internist Berl. 2006;47(4):S157–79 (356, 358–360, 362–358, passim).

Google Scholar 

Priyanka P, Chang CH, Chawla LS, Kellum JA, Clermont G, Murugan R. Vasopressor-resistant hypotension, combination vasopressor therapy, and shock phenotypes in critically ill adults with vasodilatory shock. Shock. 2022;58(4):260–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016;25(3):1057–73.

Article  PubMed  Google Scholar 

Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G 3rd, Bernard GR. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med. 2003;31(3):834–40.

Article  CAS  PubMed  Google Scholar 

Loisa P, Parviainen I, Tenhunen J, Hovilehto S, Ruokonen E. Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: a prospective randomized trial. Crit Care. 2007;11(1):R21.

Article  PubMed  PubMed Central  Google Scholar 

Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004;329(7464):480.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, Volk HD, Doecke WD, Falke KJ, Gerlach H. Immunologic and hemodynamic effects of “low-dose” hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med. 2003;167(4):512–20.

Article  PubMed  Google Scholar 

Vincent J-L, Annoni F. Vasopressor therapy. J Clin Med. 2024;13(23):7372.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kesimci E. Vasoplegia after cardiopulmonary bypass: current approaches. J Cardio-Vascular-Thoracic Anaesth Intensive Care Soc. 2024;30(4):125–31.

Google Scholar 

Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA. 2016;316(5):509–18.

Article  CAS  PubMed  Google Scholar 

Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, Winzeler B, Bingisser R, Elsaesser H, Drozdov D, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385(9977):1511–8.

Article  CAS  PubMed  Google Scholar 

Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, Alexander PE, Fei Y, Vandvik PO, Loeb M, Guyatt GH. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(7):519–28.

Article  PubMed  Google Scholar 

Yildiz O, Doganay M, Aygen B, Güven M, Keleştimur F, Tutuû A. Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care. 2002;6(3):251–9.

Article  PubMed  PubMed Central  Google Scholar 

Ragoonanan D, Allen B, Cannon C, Rottman-Pietrzak K, Bello A. Comparison of early versus late initiation of hydrocortisone in patients with septic shock in the ICU setting. Ann Pharmacother. 2022;56(3):264–70.

Article  CAS  PubMed  Google Scholar 

Alsulami M Sr, Alrojaie L, Omaer A. Early versus late initiation of hydrocortisone in patients with septic shock: a prospective study. Cureus. 2023;15(12):e50814.

PubMed  PubMed Central  Google Scholar 

Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111–24.

Article  CAS  PubMed  Google Scholar 

Kalil AC, Sun J. Low-dose steroids for septic shock and severe sepsis: the use of Bayesian statistics to resolve clinical trial controversies. Intensive Care Med. 2011;37(3):420–9.

Article  CAS  PubMed  Google Scholar